The Advisory outlines the principles and components of low barrier care, and how low barrier care may be leveraged to overcome substantial gaps in access, while also engaging individuals in treatment.

An analysis of final 2021 DAWN data presents: (1) nationally representative weighted estimates, including percent and unadjusted rates per 100,000, for all drug-related emergency department (ED) visits, (2) nationally representative weighted estimates for the top five drugs in drug-related ED visits, (3) the assessment of monthly trends and drugs involved in polysubstance ED visits in a subset of sentinel hospitals, and (4) the identification of drugs new to DAWN’s Drug Reference Vocabulary.

An analysis of 2021 preliminary data presents (1) nationally representative weighted estimates for the top five drugs in drug-related ED visits, (2) the assessment of monthly trends and drugs involved in polysubstance ED visits in a subset of sentinel hospitals, and (3) the identification of drugs new to DAWN’s Drug Reference Vocabulary.

This document provides an overview of essential information necessary for understanding mental health and substance use disorder parity and how to implement and comply with federal parity laws. This guide applies to parity laws in employer-sponsored health plans and group and individual insurance.

This guide intends to educate clinicians and other stakeholders about the harms of using more than one substance and consideration for addressing concurrent substance use (CSU) and concurrent substance use disorders (CSUD).

This guide reviews ways that telehealth modalities can be used to provide treatment for serious mental illness and substance use disorders among adults, distills the research into recommendations for practice, and provides examples of how these recommendations can be implemented.

This report provides an update on a series of topics focusing on substance use and mental health (collectively referred to as behavioral health) in the United States. SAMHSA selected specific topics and indicators in this report to represent a cross-section of the key behavioral health indicators that are assessed in SAMHSA data collections, including NSDUH. This report is intended to provide a concise, reader-friendly summary of key behavioral health measures for lay and professional audiences.

This guide supports health care providers, systems, and communities seeking to treat stimulant use disorders. It describes relevant research findings, examines best practices, identifies knowledge gaps and implementation challenges, and offers useful resources.

This guide focuses on using medication-assisted treatment for opioid use disorder in jails and prisons and during the reentry process when justice -involved persons return to the community. It provides an overview of policies and evidence-based practices that reduce the risk of overdose and relapse.

This brief provides guidance to state governments on increasing the availability of evidence-based medication-assisted treatment (MAT) in criminal justice (CJ) settings. By including the criminal justice system as a path to treatment, states may see an increase in access to and retention in treatment, and lower rates of overdoses, re-offending, and re-incarcerations. In this brief, states are provided an overview of the issue, the challenges to incorporating MAT, key considerations for establishing MAT in CJ settings, and existing standards/guidelines.